CD8A and melanoma: Signaling through the STING pathway is the upstream link that triggers type I IFN production by DCs and facilitates effective cross-priming of tumor-specific CD8+ T cells in a variety of tumor models, including colon carcinoma, melanoma, and lymphoma models [90–92].